Oncology

To help clinics meet the objectives and reporting requirements of the Oncology Care Model (OCM), Flatiron Health has developed OncoEMR, a cloud-based electronic health record (EHR) coupled with an analytics tool.

A study by researchers at the University of California, Berkeley, found that patients who have access to both the prices charged by a testing laboratory as well as reference pricing, they choose lower-cost laboratories, resulting in overall cost savings.

The monoclonal antibody daratumumab (Darzalex) has been granted breakthrough designation, the second for this drug, for use in combination with either lenalidomide and dexamethasone or bortezomib and dexamethasone, for patients with multiple myeloma who have received at least 1 prior therapy.

Michael Kolodziej, MD, has joined Flatiron Health as national medical director, Managed Care Strategy.

A collaborative pilot that includes the California Department of Public Health, is studying whether near—real-time reporting of cancer diagnoses by pathologists will permit providers to make more informed and timely treatment decisions.

This week in managed care, the Department of Justice filed suit to block 2 health insurance megamergers, a poll found that healthcare is not a top issue with voters, and a study reported that patients with cancer and dementia get better end-of-life care.

According to a news report in Nature, scientists at Sichuan University’s West China Hospital are on track to initiate a clinical trial that will administer CRISPR-Cas9—edited immune cells in patients diagnosed with lung cancer.

A letter published in The New England Journal of Medicine provides narrative of a clinical interference that has been documented with the much hailed multiple myeloma drug daratumumab.

A proof-of-concept study in ovarian cancer shows advantage of using liquid biopsy for the earlier detection of disease relapse.

While most adolescent survivors of childhood cancer have a good grip on their emotional well being, some frequently present with a combination of behavioral, emotional, and social symptoms, a new study published in the Journal of Clinical Oncology has concluded

On an earnings call yesterday, Novartis announced that the FDA has sent a complete response letter for their product pegfilgrastim, biosimilar to Neulesta.

During a health policy session at the annual meeting of the American Society of Clinical Oncology, Steven J. Katz, MD, MPH, discussed the Oncotype DX Breast Cancer Assay, and it's impact on recommendations for chemotherapy in early-stage breast cancer.